CHICAGO, Aug 16 (Reuters) - U.S. health regulators on Thursday warned doctors of the potential for Bristol-Myers Squibb Co.'s (BMY.N: Quote, Profile, Research) hepatitis B treatment to lead to resistance to the HIV virus in patients with both diseases.
